AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02916719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
Study NCT03315507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Subcutaneous Injection
Description: Eight weekly doses of PB1046.
Study NCT02755363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic manual therapy
Description: * suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs.
Study NCT02755363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: * manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres.
Study NCT01805362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomization that determine the time of treatment
Study NCT01805362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization that determine the time of treatment
Study NCT04061408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy(FSRT)
Description: 3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
Study NCT00759837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Study NCT03098290 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter-based endovascular revascularization
Description: (e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical history and physical examination
Description: medical history and physical examination
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BW and height
Description: Body weight (kg) and height (cm)
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance status
Description: ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Creatinine clearance
Description: Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Carcinoembryonic antigen and carbohydrate antigen 19-9
Study NCT02280070 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Contrasting CT
Description: Computed tomography
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse event
Description: AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
Study NCT03098290 — intervention group
Intervention type: PROCEDURE
Intervention: Bypass-Surgery
Description: Venous or alloplastic or comparable Bypass
Study NCT03098290 — intervention group
Intervention type: PROCEDURE
Intervention: Endarterectomy
Description: Endarterectomy, Patchplasty
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antigen and HCV antibody
Description: check for exclusion criteria
Study NCT00422201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Singe dose
Study NCT01234532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: orally
Study NCT01234532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT01234532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery.
Study NCT01234532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
Study NCT02041676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Study NCT02041676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual surveillance
Description: Usual surveillance of the non invasive ventilation without chest physiotherapy.
Study NCT03152149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium & olodaterol
Description: Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy for lower digestive tract
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antibody and HBc antibody
Description: Check according to hepatitis B guideline
Study NCT02280070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
Study NCT02280070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP (130mg/m2)
Description: L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
Study NCT02280070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP (85 mg/m2)
Description: L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Study NCT02280070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Study NCT02280070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Study NCT01162070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free strategy
Description: Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
Study NCT01162070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized strategy
Description: Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
Study NCT02030418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leadless Pacemaker
Description: Patients will undergo an attempted leadless pacemaker implant
Study NCT01868503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01868503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01868503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03152149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate & vilanterol
Description: Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
Study NCT02900365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early cataract surgery & IOL implantation
Description: first week cataract extraction and IOL implantation.
Study NCT02900365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: late cataract surgery & IOL implantation
Description: first month cataract extraction and IOL implantation.
Study NCT03939572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accurate step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
Study NCT03939572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deflated step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
Study NCT03939572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inflated step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
Study NCT03939572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accurate feedback + mindset intervention
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets.
Study NCT01636206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
Study NCT01636206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
Study NCT01428349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
Study NCT01428349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
Study NCT01624636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01624636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Study NCT03210402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevated night pacing on
Description: Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
Study NCT03210402 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Elevated night pacing off
Description: Device will be programmed to normal lower rates
Study NCT04716933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion Q3W
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule once daily
Study NCT04716933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching lenvatinib
Description: Oral capsule once daily
Study NCT00362843 — intervention group
Intervention type: DRUG
Intervention: [15-O]water
Study NCT03370406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Intralesional injections of 50mg/ml over a 3 week period.
Study NCT03370406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Topical application of 5% cream over a 3 week period.
Study NCT01740557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT01740557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV
Study NCT01740557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01740557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01740557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01740557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGFR-transduced Autologous T Lymphocytes
Description: Given IV
Study NCT01740557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00709306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-Detect Photos
Description: UV-Detect Photos
Study NCT00709306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV-Detect Photos
Description: UV-Detect Photos
Study NCT00709306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing
Study NCT00709306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing
Study NCT00709306 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Education
Study NCT02283255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Supervised aerobic and light muscle resistance exercise training
Study NCT02283255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training with POWERbreathe device
Study NCT02283255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise Training
Description: Usual care
Study NCT00823979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061 Dose 1
Description: UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
Study NCT00823979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061 Dose 2
Description: UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
Study NCT00823979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine
Description: Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
Study NCT03771885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated Tablet
Study NCT03771885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated Tablet
Study NCT02050594 — intervention group
Intervention type: DRUG
Intervention: Ipilimumab
Study NCT03684733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Clinical MRI breast screening examination
Study NCT03459183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrasound (85 dB; 6Hz) source
Description: the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
Study NCT03459183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (10dB below hearing threshold; 22.4 kHz) source
Description: the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
Study NCT03459183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Infrasound dummy source
Description: the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
Study NCT03459183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound dummy source
Description: the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
Study NCT00639613 — intervention group
Intervention type: PROCEDURE
Intervention: Double-balloon enteroscopy
Description: Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
Study NCT00639613 — intervention group
Intervention type: OTHER
Intervention: Standard meal test
Description: Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations.
Study NCT02431143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Study NCT04083651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
Study NCT04083651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
Study NCT01928004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
Study NCT01928004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reline
Description: conventional reline of the existing mandibular complete denture
Study NCT00303849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA
Study NCT00303849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00303849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV